ANGELA CLAY: Open Payments
NPI 1992899645 · FORDLAND, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$524 in 29 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $328 · 2025 $524
Food & beverage: $479Education: $45
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $169 |
| Novo Nordisk Inc | 5 | $80 |
| Lilly USA, LLC | 2 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| ABBVIE INC. | 2 | $44 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| Grifols USA, LLC | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: INGREZZA, Ozempic, REXULTI, VRAYLAR, CAPLYTA, COBENFY, Prolastin-C Liquid, ABILIFY ASIMTUFII.
Industry payments across MO — which companies pay providers there.
